RCEL Overview

AVITA Medical, Inc. is a therapeutic acute wound care company. The Company’s technologies optimize wound healing, effectively accelerating the time to patient recovery. At the forefront of its platform is the RECELL System for the treatment of thermal burn wounds and full-thickness skin defects. RECELL harnesses the healing properties of a patient’s own skin to create Spray-On Skin Cells, offering a solution for improved clinical outcomes at the point-of-care. In the United States, it also holds the exclusive rights to market, sell, and distribute Cohealyx, an AVITA Medical-branded collagen-based dermal matrix, and PermeaDerm, a biosynthetic wound matrix. Its technologies are designed to optimize skin restoration procedures, effectively accelerating patient healing and recovery. Its solutions improve the healing outcomes for patients with traumatic injuries and surgical repairs, addressing critical healing needs that arise from unpredictable and life-changing events.

Wall Street analysts forecast RCEL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RCEL is4.25 USD with a low forecast of 3.00 USD and a high forecast of 5.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

AVITA Medical Inc revenue for the last quarter amounts to 17.61M USD, decreased -4.30

AVITA Medical Inc. EPS for the last quarter amounts to -0.38 USD, decreased -13.64

AVITA Medical Inc (RCEL) has 226 emplpoyees as of March 17 2026.

Today RCEL has the market capitalization of 141.52M USD.